-+ 0.00%
-+ 0.00%
-+ 0.00%

Sartorius Stedim Biotech Affirms FY26 Sales Revenue Growth Outlook

MT Newswires·10/22/2026 01:46:44
Listen to the news
01:46 AM EDT, 10/22/2026 (MT Newswires) -- Sartorius Stedim Biotech (DIM.PA) reiterated its guidance for growth in sales revenue for full-year 2026. The Paris-listed biopharmaceutical group continues to expect a 6% to 10% increase in sales revenue for the year in constant currencies. Excluding tariff-related effects, the company expects operational growth to be at the midpoint of the range.